New molecular entity

Citation metadata

Date: Jan. 2013
From: Formulary(Vol. 48, Issue 1)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 614 words
Lexile Measure: 1570L

Document controls

Main content

Article Preview :

Linzess

Linaclotide

IRONWOOD PHARMACEUTICALS AND FOREST PHARMACEUTICALS

A guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults

On August 30, 2012, FDA approved linaclotide (Linzess, Ironwood Pharmaceuticals and Forest Pharmaceuticals) for the treatment of chronic idiopathic constipation and irritable bowel syndrome (IBS) with constipation in adults. Approximately 63 million people are affected by chronic constipation, according to the National Institutes of Health. For those individuals who experience persistent constipation and do not respond to standard therapy, they are diagnosed with chronicidiopathic constipation. IBS affects about 15.3million people. IBS withconstipation, a subtype of IBS, is characterized byabdominal pain and hard or lumpy stools at least25% of the time and loose or watery stools less than25% of the time. Linaclotide has been approved with a black-box warning that the drug should not be prescribed for patients 17 years of age and younger due to deaths...

Source Citation

Source Citation   

Gale Document Number: GALE|A319382026